Hepatitis B virus (HBV) is an important co-morbidity in the HIV epidemic. A retrospective chart review was performed of HIV-infected patients with no previous antiretroviral history enrolled in a Swaziland clinic from January 2009 to May 2011. The seroprevalence of HBV surface antigen (HBsAg) was calculated and the data were analyzed using Mann-Whitney U and Fisher's exact tests. A total of 1282 patients were included in analysis. Five hundred were children aged <15 years. Overall HBsAg seroprevalence was 3.7% (1.4% of children and 5.1% of adults). Prevalence in under-5s was low (0.4%). Among adult women and men, prevalence was 4.2% and 9.8%, respectively (P = 0.022). Median alanine aminotransferase level was 19 U/L in the HBsAg-negative adults and 25 U/L in the HBsAg-positive adults (P = 0.005). Given the number of patients found to be HBsAg-positive, especially among adults, it is important for antiretroviral programmes to consider universal screening and strategically utilize medications that have been found effective in treating both HBV and HIV.
LacombeKBotteroJLemoineMHIV/hepatitis B virus co-infection: current challenges and new strategies. J Antimicrob Chemother2010;65:10–7
2.
LewdenCSalmonDMorlatPCauses of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol2005;34:121–30
3.
BicaIMcGovernBDharRIncreasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis2001;32:492–7
4.
Salmon-CeronDLewdenCMorlatPLiver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol2005;42:799–805
5.
ThioCLSeabergECSkolaskyRHIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet2002;360:1921–6
6.
ThioCL. Hepatitis B and human immunodeficiency virus coinfection. Hepatology2009;49:S138–145
7.
AdewoleOOAnteyiEAjuwonZHepatitis B and C virus co-infection in Nigerian patients with HIV infection. J Infect Dev Ctries2009;3:369–75
8.
AlterMJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol2006;44:S6–9
9.
PatelPDavisSTolleMPrevalence of hepatitis B and hepatitis C coinfections in an adult HIV centre population in Gaborone, Botswana. Am J Trop Med Hyg2011;85:390–4
10.
Diop-NdiayeHTouré-KaneCEtardJFHepatitis B, C seroprevalence and delta viruses in HIV-1 Senegalese patients at HAART initiation (retrospective study). J Med Virol2008;80:1332–6
11.
NyirendaMBeadsworthMBStephanyPPrevalence of infection with hepatitis B and C virus and co-infection with HIV in medical inpatients in Malawi. J Infect2008;57:72–7
12.
WHO. Swaziland: WHO and UNICEF Estimates of National Immunization Coverage. See http://www.who.int/immunization_monitoring/routine/immunization_coverage/en/index4.html, (last checked 15 November 2012)
13.
WHO. Antiretroviral Therapy of HIV Infection in Infants and children: towards Universal Access. Recommendations for a Public Health Approach. Geneva, Switzerland: World Health Organization, 2006
14.
ModiAAFeldJJ. Viral hepatitis and HIV in Africa. AIDS Rev2007;9:25–39
15.
Gomez-GonzaloMCarreteroMRullasJThe hepatitis B virus X protein induces HIV-1 replication and transcription in synergy with T-cell activation signals: functional roles of NF-kappaB/NF-AT and SP1-binding sites in the HIV-1 long terminal repeat promoter. J Biol Chem2001;276:35435–43
16.
ChunHMRoedigerMPHullsiekKHHepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. J Infect Dis2012;205:185–93
17.
HoffmannCJThioCL. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis2007;7:402–9
18.
BarthREHuijgenQTaljaardJHepatitis B/C and HIV in sub-Saharan Africa: an association between highly prevalent infectious diseases. A systematic review and meta-analysis. Int J Infect Dis2010;14:e1024–1031
19.
RouetFChaixMLInwoleyAFrequent occurrence of chronic hepatitis B virus infection among West African HIV type-1-infected children. Clin Infect Dis2008;46:361–6
20.
AshirGMRabasaAIGofamaMMStudy of hepatic functions and prevalence of hepatitis B surface antigenaemia in Nigerian children with human immunodeficiency virus infection. Niger J Med2009;18:260–2
21.
ChakrabortyRReesGBourbouliaDViral coinfections among African children infected with human immunodeficiency virus type 1. Clin Infect Dis2003;36:922–4
22.
UNICEF, WHO. Immunization Summary. A Statistical Reference Containing Data Through 2009. New York, NY: The United Nations Children's Fund, 2011
23.
PsevdosGKimJHSuhJSPredictors of loss of hepatitis B surface antigen in HIV-infected patients. World J Gastroenterol2010;16:1093–6
24.
BwogiJBrakaFMakumbiIHepatitis B infection is highly endemic in Uganda: findings from a national serosurvey. Afr Health Sci2009;9:98–108
25.
OttJJStevensGAGroegerJGlobal epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine2012;30:2212–9
26.
WHO Regional Office for Europe. Management of Hepatitis B and HIV Coinfection. Clinical Protocol for the WHO European Region. Copenhagen, Denmark: World Health Organization, 2011
27.
IdokoJMeloniSMuazuMImpact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria. Clin Infect Dis2009;49:1268–73
28.
lsaSEGwamzhiLNAkoloCA prospective cohort study of immunologic and virologic outcomes in patients with HIV/AIDS and hepatitis virus co-infection in Jos, Nigeria. Niger J Med2010;19:279–85
29.
JobartehMMalfroyMPetersonISeroprevalence of hepatitis B and C virus in HIV-1 and HIV-2 infected Gambians. Virol J2010;7:230
30.
EkeACEkeUAOkaforCIPrevalence, correlates and pattern of hepatitis B surface antigen in a low resource setting. Virol J2011;8:12
31.
LimSGWaiCTRajnakovaAFatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. Gut2002;51:597–9
32.
PetersPJMarstonBJ. Preventing deaths in persons with HIV/hepatitis B virus coinfection: a call to accelerate prevention and treatment efforts. J Infect Dis2012;205:166–8
33.
Swaziland Ministry of Health. National Guidelines on the Comprehensive HIV Package of Care for Adults and Adolescents in Swaziland. Mbabane, Swaziland: Swaziland Ministry of Health, 2010
34.
WHO. Use of tenofovir in HIV-infected Children and Adolescents: A public health perspective. Geneva, Switzerland:World Health Organization, 2012
